Fluconazole dosing varies based on the type of infection it’s being used to treat. Most fungal infections require a loading dose on the first day of treatment, followed by daily maintenance doses for ...

What is the aim of this review? The aim of this Cochrane Review was to find the best therapy to reduce the risk of death from cryptococcal meningitis in HIV-positive individuals. The Cochrane review ...

When Peter Redweik’s physicians finally realized that his splitting headaches, slurred speech and stumbling gait were caused by cryptococcal meningitis — a severe inflammation of his brain caused by a ...

Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases. A new, ...

A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has entered Phase II clinical trials in Malawi and ...

Dar es Salaam / Lilongwe / Geneva — 15 April 2025 — A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has ...

A new WHO Academy course on the Management of cryptococcal disease in people living with HIV provides learners with the knowledge they need to give high quality care to people with cryptococcal ...

Introduction: We report the case of a heart transplant patient on chronic immunosuppression diagnosed with cryptococcal meningitis. Up to 5% of solid organ transplant patients develop cryptococcosis, ...

Improving outcomes for patients requires urgent efforts to reduce the price of treatments and increase access to drugs. When Zikhona, a young woman from New Crossroads in Cape Town, arrived at ...

Worldwide, cryptococcal meningitis kills up to 180,000 persons annually and is the most common cause of nonviral meningitis in the United States. Besides patients with immunosuppression due to human ...